Pharmacology of the anti-virals and their use in ophthalmology. Mainly on their principals and mechanism of action.
* This is short presentation as it was a small part of our medical retina team presentation where the topic was on CMV Retinitis.
9. In what preparations do they
exist?
Zirgan ointment 0.15% - ophthalmic gel
Cytovene 500 mg
10. What are the effects of the
body on the drug?
Absorption:
• Oral – very limited
• t ½ : 2-6 hours
Distribution: All tissues
• Especially CSF and ocular tissue
Excretion: 80-90% unchanged in urine
11. When do we use Ganciclovir?
1. Herpes Epithelial Keratitis
Ganciclovir Gel 0.15% (Zirgan)
2. CMV Retinitis
Initial: IV 5mg/kg BD for 14-21 days
Maintenance:
IV 5mg/kg OD or
IV 6 mg/kg OD for 5 days/week
12. What are the side effects?
Bone marrow supression
Neutropenia
Granulocytopenia
TOXICITY
Potential carcinogen
Teratogen
Inhibits spermatogenesis
13. Valganciclovir
Prodrug of Ganciclovir
Taken orally
Changed to Ganciclovir by intestinal/hepatic esterase
14. In what preparations do they
exist?
Valcyte Tablet 450 mg
Valcyte Oral Solution 50 mg/mL
15. What are the effects of the
body on the drug?
Absorption:
• Well-absorbed especially with fatty meals
Distribution:
• Well distributed especially CSF and ocular tissues
Metabolism:
• In liver & intestine changed to Ganciclovir
Excretion: 80-90% in urine
16. When do we use Valganciclovir?
CMV Retinitis
Initial: Oral 900 mg BD x 21 days
Maintenance:
Oral 900 mg OD
19. How come it doesn’t work in
some cases?
• Deficient viral thymidine-kinase
.
• Mutations to viral thymidine-kinase or DNA
polymerase
20. Which virus does it attack?
Herpes-simplex 1
Herpes-simplex 2
Varicella-zoster virus
Epstein-Barr virus
Cytomegalovirus
Most activity
21. In what preparations do they
exist?
Zovirax ointment 3%
Tablet Aciclovir 200 mg / 400 mg
22. What are the effects of the
body on the drug?
Absorption:
• Poor water-soluble
• Poor oral bioavailability
Distribution: High distribution rate
• T ½: 3 hours
Metabolism: Small amounts – liver
Excretion: 62-90% unchanged in urine
23.
24. When do we use Aciclovir?
Herpes-Zoster Ophthalmicus Herpex Simplex Blepharitis
Herpes keratitis
25. What are the side effects?
Systemic
Nausea, vomiting
Encephalopathy IV
Local
SPK
Allergy
Editor's Notes
MECHANISM OF ACTION
Ganciclovir (9-[(1,3,-dihydroxy-2-propoxy)methyl] guanine, or DHPG) is an acyclic analog of the nucleoside guanosine. The drug is converted intracellularly to ganciclovir 5'-monophosphate by a viral kinase, which is encoded by the cytomegalovirus (CMV) gene UL97 during infection. Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells than uninfected cells.
Ganciclovir triphosphate is a competitive inhibitor of deoxyguanosine triphosphate incorporation into DNA and preferentially inhibits viral DNA polymerases more than cellular DNA polymerases. In addition, ganciclovir triphosphate serves as a poor substrate for chain elongation, thereby disrupting viral DNA synthesis by a second route [1-3].
Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase or DNA polymerase, altering substrate sensitivity
Acyclovir (9-[2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV). After intracellular uptake, it is converted to acyclovir monophosphate by virally-encoded thymidine kinase. This step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate by cellular enzymes.
Acyclovir triphosphate competitively inhibits viral DNA polymerase by acting as an analog to deoxyguanosine triphosphate (dGTP). Incorporation of acyclovir triphosphate into DNA results in chain termination since the absence of a 3' hydroxyl group prevents the attachment of additional nucleosides. Acyclovir triphosphate has a much higher affinity for viral DNA polymerase than for the cellular homolog, yielding a high therapeutic ratio
Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase or DNA polymerase, altering substrate sensitivity